News
Zacks Small Cap Research on MSN2d
OTC Markets Hosts Virtual Investor Presentation with HH Kim, President and CEO of MetaVia Inc., and David Bautz, PhD, Senior Analyst at Zacks SCRHello, and welcome to Virtual Investor Conferences. On behalf of the Life Sciences Investor Forum and our co-host Zacks Small Cap Research, we're very pleased you joined us for our quarterly ...
Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.
Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 ...
People living in more disadvantaged neighborhoods may be more likely to have biomarkers for inflammation and Alzheimer's ...
CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...
Rivus Pharmaceuticals’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the ...
The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...
Investing.com - Morgan Stanley (NYSE: MS) has reiterated an Equalweight rating and DKK550.00 price target on Novo Nordisk ...
Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback